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Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely
drug refractory cohort of patients with epileptic encephalopathies (EE).
Method: A multicenter, retrospective cohort study recruiting all patients treated with EE
who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.
Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were
treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at
12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV
of 310 months. Three patients were seizure free during the baseline. At 3 months, 20
(45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV
including three who were seizure free during baseline) were either seizure free (n= 4; 9%,
three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or
50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported
in two (5%) patients, while there was no change in the seizure frequency of the other
patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two
(5%) free from seizures for more than six months and in nine patients (20%, with one
[2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events
were predominantly of psychobehavioural nature and were observed in 16%.
Significance: In this retrospective analysis the rate of patients with a 50% seizure
reduction under BRV proofed to be similar to those seen in regulatory trials for focal
epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be
considered in patients with psychobehavioral adverse events while on levetiracetam.
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INTRODUCTION
Brivaracetam (BRV), the second substance in the racetam class
of anti-epileptic drugs (AEDs), was approved in the EU and
USA in 2016 as adjunct therapy for epilepsy with focal onset
seizures whether or not secondary generalization is present.
Promising results concerning efficacy, tolerability and safety of
BRV were demonstrated in a number of clinical trials (1–7). Like
levetiracetam (LEV) BRV primarily acts as inhibitory ligand at
the synaptic vesicle protein 2A (SV2A). Compared to LEV, BRV
shows a 30-fold increased affinity to its structural target (8–12).
Switching patients from LEV to BRV at a ratio of 10:1 to 15:1 may
reduce adverse drug events in patients who respond well to LEV
but develop drug-related sedation or BAEs (behavioral adverse
events) (1, 7, 13).
Epileptic encephalopathies (EE) are a heterogeneous group
of epilepsy syndromes (14, 15) in which epileptic activity
leads to progressively greater levels of cognitive and behavioral
impairment as it would be expected only as a result of the
underlying structural or genetic pathology. According to ILAE
guidelines (International League Against Epilepsy), common EE
syndromes with characteristic electroclinical manifestations are
Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), West
Syndrome (WS) and EE with continuous spike-and-wave during
sleep (CSWS). In addition, there is a heterogeneous group of
diseases withmetabolic, or structural aetiologies predisposing the
development of EEs, such as Landau-Kleffner Syndrome (LKS),
Tuberous Sclerosis Complex (TSC) or Unverricht-Lundborg
Syndrome (UVR). Moreover, several epileptogenic mutations
like SCN9A, KCN2A or GRIN-2B have been shown to be
associated with EE in their course of disease. The majority of EE
patients develop refractory epilepsies and suffer from relapsing
seizures of heterogeneous semiologies. Frequent hospitalization
associated with the need for extended medical and nursing
care place major social, interpersonal, and economic burden on
patients, caregivers and society (14–18).
The purpose of this multicenter study was to evaluate efficacy
and tolerability of BRV in patients with EE.
PATIENTS AND METHODS
A retrospective data analysis with EE patients who received
at least one dose of BRV between 2016 and 2017 was
performed at eight German epilepsy centers (Frankfurt,
Greifswald, Kork, Leipzig, Marburg, Münster, Neuruppin,
and Rotenburg/Wümme). There is no third party funding
or sponsoring to report. This study was approved by the
ethics committee. STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) guidelines were followed
(19).
The average seizure frequency of the last three months prior
to the initiation of BRV was accepted as the baseline frequency.
Three, 6 and 12 months retention rates were calculated. Terminal
remission defined patients reaching seizure freedom throughout
the subsequent follow up periods. For the purposes of this study,
a 25% seizure reduction was assumed if seizure frequencies
declined by 25 to 50% compared to the baseline whereas a
50% seizure reduction described a reduction of the seizure
frequency above 50%. Patients who showed less than a 25%
seizure reduction were assumed to be non-responders. A seizure
increase was defined as any increase of seizure frequencies
greater 25%. Further details of analysis and the definition of
BAEs are available in Steinig et al. (20). Data acquisition was
performed using anonymised, standardized reporting forms and
statistical analysis by IBM SPSS Statistics, Version 22.0 (IBM
Corp, Armonk, NY, U.S.A.). Kaplan-Meier survival curves were
used to estimate retention time; Chi-Square and log-rank tests
were used for statistical analysis with p-values <0.05 treated as
statistically significant.
RESULTS
Patient Characteristics at Baseline
Forty-four patients (27 male; 61% male), mean age 28.8 years
(±14.2, range 6-62, nine children or adolescents <18 years
[21%]), were included in this study. Themost frequent aetiologies
of EE in our cohort were LGS (n= 20, 45.5%), TSC (n= 3, 6.8%),
UVR (n = 2, 4.5%), and CSWS (n = 2, 4.5%). Moreover, several
patients displayed other well-defined syndromes associated with
EE, such as DS, AS and Neuronal Ceroid Lipofucinosis (each
n = 1, 2%) or epileptogenic mutations, such as SCN9A, KCN2A
and GRIN-2B (each n = 1, 2%). Mean epilepsy duration at
baseline was 24.4 ± 15 years (median 23; range 0–57 years).
Epilepsy onset was at a mean age of 4.4 ± 6.3 years (median
2; range 0–27 years). In 18 patients (40.9%), mRS (modified
Rankin Scale) of 3–5 indicated moderate to severe impairment.
Mean AED number at start of BRV was 2.9 ± 0.9 (median:
3, range: 1–4 AEDs). The most frequently prescribed drugs at
baseline were: valproate (VPA, n= 27, 61%); LEV (n= 24, 55%);
lamotrigine (LTG, n = 24, 55%); clobazam (CLB, n = 18, 41%);
carbamazepine (CBZ, n = 14, 32%), topiramate (TPM, n = 14,
32%), and zonisamide (ZNS, n = 14, 32%). A drug refractory
course was present in all patients, they have failed amean number
of 4.4 ± 4.3 AEDs in the past (median 3.5, range 0–17; current
AEDs not included). A total of 37 patients (84.1%) had exposure
to LEV during their lifetime. Details are presented in Table 1.
The mean monthly seizure frequency during baseline period
was 54.9 ± 76.9 (median 30, range 0–400). In three patients
(6.8%) no seizures during baseline period were reported,
however, they were switched due to TEAE (Treatment Emergent
Adverse Event) under LEV or another AED. Focal onset seizures
with preserved awareness were reported in three patients (7%),
while 20 patients (46%) suffered from focal onset seizures with
impaired awareness. 27 patients (61%) described focal onset
seizures evolving into bilateral tonic-clonic seizures. Atypical
absence seizures were reported by 14 (32%) and myoclonic
seizures by 18 patients (41%). In addition, 20 patients (46%)
described other generalized seizure types, such as tonic or atonic
seizures.
Treatment With Brivaracetam
The initial daily dosage of BRV for patients who were not taking
LEV at start of BRV varied between 25mg and 100mg (mean
66.3mg ± 26.0mg, median 50mg). Median titration time was 6
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days (mean 13.7 ± 15.8 days), the target dose ranged between
100mg and 200mg (mean 138.5 ± 50.6mg, median 100mg).
The total number of patients switching from LEV to BRV at a
median 15:1 ratio (mean 16.2:1, range 5:1 to 50:1) was 24 (55%),
of whom 21 switched overnight and three overlapped LEV and
BRV. Patients switched from LEV to BRV at an initial dose in the
range 25mg to 300mg (mean 122.1 ± 72.1mg, median 100mg),
with a target dose in the range 60mg to 300mg (mean 175.2 ±
70.1mg, median 187.5mg).
Retention, Responder Rate, and Seizure
Free Patients
The probability that a patient would still be on BRV treatment
after 3 months was 65%, respectively 52% after 6 months and 41%
after 12 months. The most common reasons for discontinuing
BRV were lack of efficacy (n = 12, 27%), adverse events (n = 5,
11%); or both (n= 2, 5%).
At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis
considering all patients that started BRV including three who
were seizure free during baseline) were either seizure free (n= 4;
9%, three of them already seizure-free at baseline) or reported at
least 25% (n= 4; 9%) or 50% (n= 12; 27%) reduction in seizures.
There was no change in the frequency of seizures in 21 patients
(48%), an increase in seizure frequency was reported in two
(5%) patients. In one patient response was not well quantifiable.
Table 2 shows the response according to clinical characteristics.
A 50% long-term responder rate was apparent in 19 patients
(43%), with two (5%) free from seizures for more than 6 months
and in nine patients (20%, with one [2%] free from seizures) for
more than 12 months. The mean exposure time to BRV was 211
days, ranging from one day to 24 months (median 140 days).
The total exposure time to BRV in this study was 310 months.
Retention rates were calculated and plotted using the Kaplan–
Meier survival curves for all patients (Figure 1A) and depending
on the LEV to BRV switch (Figure 1B). No significant difference
was observed between patients who started on BRV and those
who switched from LEV (log-rank p-value: 0.515). At the final
follow-up, the daily BRV dose ranged from 50mg to 300mg
(mean 131.5 ± 86.2mg, median 150mg); three patients (6.8%)
had a daily dose greater than 200mg.
Treatment-Emergent Adverse Events
TEAEs were reported in seven (16%) patients while being treated
with BRV. There were six (14%) cases of BAE, one (2 %) of
somnolence and one (2%) of bruxism. BAE were observed in four
patients that had had BAEwhile exposed to LEV (n= 4/18), while
two patients had BAE on BRV who had had no BAE on LEV or
were not exposed to LEV in the past (n= 2/26, p= 0.35). Details
are presented in Table 3.
DISCUSSION
This multicenter retrospective study examined the efficacy
of BRV and its tolerability in a cohort of 44 EE patients
who represent a severely affected subgroup with usually drug
refractory epilepsy and frequent seizures (15, 21). The burden
placed on these patients, their caregivers and society makes
TABLE 1 | Clinical and sociodemographic characteristics of the cohort (n = 44).
Age (years)
Mean ± SD 28.3 ± 14.5
Median 26.0
Range 3–62
Mean age at onset of epilepsy (years)
Mean ± SD 4.4 ± 6.2
Median 2.0
Range 0–27
Epilepsy duration (years)
Mean ± SD 24.4 ± 15.0
Median 23.0
Range 0–57
Sex n (%)
Male 27 (61.4)
Female 17 (38.6)
Number of concomitant AEDs at start of BRV
Mean ± SD 2.9 ± 0.9
Median 3.0
Range 1–4
Previously failed AEDs (without current)
Mean ± SD 4.4 ± 4.3
Median 3.5
Range 0–17
Seizure semiology n (%)
Focal onset seizures with preserved awareness 3 (6.8)
Focal onset seizures with impaired awareness 20 (45.5)
Focal to bilateral tonic-clonic seizures 27 (61.4)
Myoclonic seizures 18 (40.9)
Atypical absence seizures 14 (31.8)
Other generalized seizures 20 (45.5)
Syndrome/etiology n (%)
Lennox-Gastaut-Syndrome (LGS) 20 (45.5)
Tuberous sclerosis complex (TSC) 3 (6.8)
Unverricht-Lundborg-Syndrome (UVR) 2 (4.5)
Continuous Spike Waves in Sleep (CSWS) 2 (4.5)
Dravet-Syndrome 1 (2.3)
SCN9A mutation 1 (2.3)
Neuronal Ceroid Lipofuscinosis (NCL) 1 (2.3)
KCN2A mutation 1 (2.3)
GRIN-2B mutation 1 (2.3)
RBFOXI mutation 1 (2.3)
Angelman-Syndrome 1 (2.3)
other 10 (22.7)
AED, anti-epileptic drug; SD, standard deviation; BRV, brivaracetam.
outcome research in patients with EEs relevant and important.
New AEDs including cannabidiol and fenfluramine are being
developed for some EE patient subgroups (14–17) and there are
few precision medicine approaches for single syndromes leading
to EE, such as everolimus in TSC or ketogenic diet in Glut1-
deficency. To date, there is only insufficient information on the
efficacy and tolerability of BRV in this special subgroup. Data
on this cohort, with aggregated 310 month exposure to BRV
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TABLE 2 | Clinical characteristics and outcome on 3-months-follow-up (n = 43, response in 1 patients not quantifiable).
Patients Non responders >25% response >50% Response Subgroup of seizure
free patients
n % (n)
Total 43 53.5 (23) 9.3 (4) 37.2 (16) 9.3 (4)
SEX
Male 26 50.0 (13) 3.8 (1) 46.2 (12) 15.4 (4)
Female 17 52.6 (10) 15.8 (3) 21.1 (4) 0.0 (0)
AGE RANGE
<18 years 9 44.4 (4) 11.1 (1) 44.4 (4) 22.2 (2)
≥18 years 34 55.9 (19) 11.8 (4) 32.3 (11) 5.9 (2)
INITIAL BRV DOSAGE
≤100mg 21 47.6 (10) 19.0 (4) 33.3 (7) 9.5 (2)
100–199mg 14 57.1 (8) 0.0 (0) 42.9 (6) 7.1 (1)
>200mg 5 60.0 (3) 0.0 (0) 40.0 (2) 0.2 (1)
LEV STATUS
Direct switch from LEV to BRV 23 56.5 (13) 4.3 (1) 39.1 (9) 17.4 (4)
Start of BRV with previous exposure to LEV 13 61.5 (8) 7.7 (1) 30.8 (4) 0.0 (0)
Start of BRV without previous exposure to LEV 7 28.6 (2) 28.6 (2) 42.9 (3) 0.0 (0)
PREVIOUSLY FAILED AEDs (WITHOUT CURRENT)
0–1 14 42.9 (6) 0.0 (0) 57.1 (8) 21.4 (3)
≥ 2 25 56.0 (14) 16.0 (4) 28.0 (7) 0.04 (1)
NUMBER OF AEDs AT START OF BRV
0–1 3 66.6 (2) 0.0 (0) 33.3 (1) 33.3 (1)
2 8 62.5 (5) 0.0 (0) 37.5 (3) 25.0 (2)
≥3 28 46.4 (13) 14.3 (4) 39.3 (11) 3.6 (1)
SEIZURE SEMIOLOGY
Focal onset seizures with or without preserved awareness 19 63.1 (12) 10.5 (2) 26.3 (5) 5.3 (1)
Focal to bilateral tonic-clonic seizures 26 42.3 (11) 15.4 (4) 42.3 (11) 7.7 (2)
Other generalized seizures 31 48.4 (15) 6.5 (2) 45.2 (14) 3.2 (1)
BRV, brivaracetam; LEV, levetiracetam; AEDs, antiepileptic drugs.
FIGURE 1 | Retention of brivaracetam (BRV) in the complete cohort (A) and in patients with (LEV) or without levetiracetam upon start of brivaracetam (B) (w/o,
without).
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and follow-ups of up to 24 months, are informative in this
respect.
The cohort showed retention rates of 65% at 3 months, 52%
at 6 months and 41% at 12 months which is in line with other
BRV post-marketing studies (13, 20, 22, 23), and compare with
results from other AEDs in frequent use as eslicarbazepine acetate
(ESL), LCM, LTG, LEV, perampanel (PER), topiramate (TPM),
VPA, and ZNS in patients with focal epilepsies (20, 24–29).
Unfortunately, only limited information is available on efficacy
and tolerability of AEDs in EE patients. This cohort showed
a 50% responder rate of 36% at the 3-month follow-up with
additional four patients (9%) being seizure-free. Of these four
patients three had been already seizure free during baseline
period. The corresponding figures were 43% and 5% at the
6 months follow-up and were 20% and 2% at more than 12
months follow up. These results are in line with other studies
using different AEDs in EE (for the most part LGS and DS)
including LEV (47%) (30), TPM (40-48%) (31, 32), felbamate
(FBM, 50%) (33, 34), ZNS (53 %) (35), and PER (46%) (36)
at 3-month follow-up. Other AEDs, and particularly rufinamide
(RUF) and cannabidiol (CBD), have been thought promising for
EE, and both rendered comparable results with 50% responder
rates of 31–48% for RUF (37–39) and 44–50% for CBD (40, 41).
Currently, especially the use of CBD as an antiepileptic drug is the
subject of some controversy and there is a need for randomized
controlled trials (RCT) to verify these findings (42, 43). It has
been demonstrated that neurostimulation via an implanted vagal
nerve stimulator has similar efficacy with 50% responder rates of
43% (44). Overall, responder rates in EE of≥50% can be achieved
in 30% to 45% of EE patients. While results appear to be similar
for different AEDs, there may be differential effects regarding
seizure types. PER, for example, may be especially effective for
myoclonic or bilateral tonic-clonic seizures (45–47).
No significant difference in efficacy was seen between patients
who switched to BRV from LEV and those who either started
BRV with LEV treatment at some point in the past or those
who had not been treated with LEV before. These findings
contrast with other publications that reported lower responder
rates with previous exposure to LEV. The difference may result
from the small size of our cohort (3, 4), with the limited number
of EE patients precluding statistical analysis of possible clinical
response predictors. Notwithstanding that, male patients who
had a smaller number of previously failed AEDs and a generalized
seizure semiology (generalized tonic clonic, myoclonic, absence
seizures) trended toward a better response with 50% responder
rates exceeding 50%. Rapid titration of BRV (mean 10 days,
median 5.5 days) to a mean daily dose of 153.1mg (median
135mg) with three patients on a daily dose of more than 200mg
makes under-dosing very unlikely in this study.
BRV was well tolerated in this often severely by BAEs affected
subgroup, with only seven patients (16%) reporting TEAE
and withdrawal of BRV from only four patients (9%). These
findings compare with other post-marketing studies of BRV
which showed TEAE in 37–38% (13, 20); the dominant BAEs
were symptoms like irritability and aggression (16%). Taking
into account of the possibility that this retrospective study may
show reporting bias, a comparison with TEAE frequencies seen
in trials of RUF (55–70%) (37, 38) and CBD (33–58%) (48,
49), it would seem that tolerance of BRV is good, but careful
consideration should be given before using it in patients with
a pre-existing intellectual disability (50). The most common
reasons for discontinuing BRV were lack of efficacy (23%) and
adverse drug events (11%) or both (5%).
Psychobehavioral TEAE were closely followed-up and were
present in six patients (14%) while on BRV, leading to
discontinuation of BRV in four patients (9%). Psychobehavioral
TEAE while on LEV were reported in 14 patients (32%) at switch
or in the past while exposed to LEV, details Table 3. Therefore,
patients who experience psychobehavioral TEAE associated with
LEV might be offered a switch to BRV.
As the study depends on interviews, underreporting of
TEAE cannot be ruled out, representing a possible weakness
in this study, but all visits and interviews were conducted by
epilepsy specialists and documented immediately, minimizing
the risk of such bias. Other major limitations of the study are
the retrospective chart review and the relatively low number
of patients that might lead to unreliable findings and large
variability regarding seizure control. The retention rate is a
TABLE 3 | Characteristics of treatment-emergent adverse events (TEAEs) and their frequency (n = 44).
TEAE under BRV TEAE only under
LEV*
TEAE under LEV
and BRV
reported
n(%)
leading
to withdrawal
n(%)
reported
n(%)
reported
n(%)
Overall 7 (15.9) 4 (9.1) 18 (40.9) 3 (6.8)
CNS related 1 (2.3) 1 (2.3) 5 (11.4) 1 (2.3)
Sedation/somnolence 1 (2.3) 1 (2.3)
psychiatric 6 (13.6) 4 (9.1) 14 (31.8) 2 (4.5)
Irritability 4 (9.1) 2 (4.5)
Aggression 3 (6.8) 2 (4.5)
Other 1 (2.3) 0 (0.0) 2 (4.5) 1 (2.3)
Bruxism 1 (2.3) 0 (0.0)
BRV, brivaracetam; LEV, levetiracetam; *reported at switch or in the past while exposed to LEV.
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naturalistic functional endpoint encompassing efficacy, quality
of life, tolerability, and safety, also no prospective baseline is
required (51, 52). Measurement of retention might prove less
prone to reporting bias as the prescription of medication is
usually well documented.
CONCLUSIONS
BRV is effective and well-tolerated in patients with EE and
the pattern of TEAEs compares with other AEDs in frequent
use. Efficacy of BRV does not seem to depend on whether
patients have previously been exposed to LEV or not. A direct
switch from LEV to BRV is feasible for patients with EE.
Taken in conjunction with other post-marketing studies on
focal or idiopathic generalized epilepsies, it seems that BRV
is a reasonable treatment option for patients with epileptic
encephalopathies.
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